Adjuvant mFOLFOX6 +/- Cetuximab in Patients With KRAS Mutant Resected Stage III Colon Cancer: NCCTG Intergroup Phase III Trial N0147.
   Google Scholar   
Citation:
J. Clin. Oncol. vol 28 (15s) abstr 3508
Year:
2010
Type:
Abstract
Sub type:
Poster General
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
SDC:
No
Parents:
None
Children:
477  
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                     
Networks:
 
Study
N0147
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: